Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short-term Investments (2019 - 2025)

BridgeBio Pharma's Short-term Investments history spans 7 years, with the latest figure at $17.4 million for Q4 2025.

  • For Q4 2025, Short-term Investments changed N/A year-over-year to $17.4 million; the TTM value through Dec 2025 reached $17.4 million, changed N/A, while the annual FY2025 figure was $17.4 million, N/A changed from the prior year.
  • Short-term Investments for Q4 2025 was $17.4 million at BridgeBio Pharma, up from $3.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $459.2 million in Q2 2021 and bottomed at $131000.0 in Q1 2024.
  • The 5-year median for Short-term Investments is $49.8 million (2023), against an average of $144.0 million.
  • The largest annual shift saw Short-term Investments soared 21329.38% in 2022 before it tumbled 99.74% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $177000.0 in 2021, then skyrocketed by 21329.38% to $37.9 million in 2022, then surged by 55.42% to $58.9 million in 2023, then surged by 136.49% to $139.4 million in 2024, then tumbled by 87.55% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Short-term Investments are $17.4 million (Q4 2025), $3.0 million (Q3 2025), and $7.9 million (Q2 2025).